Lifecycle Management of Potency Assays and Specifications in CGT Programs The management of potency assays and specifications is crucial in the development and commercialization of cell and gene therapy (CGT) products. These assays are integral to ensuring that products meet regulatory requirements and provide efficacy and safety for patients. This article aims to provide a comprehensive step-by-step guide to the lifecycle management of potency assays and specifications in CGT programs, focusing primarily on the requirements set forth by the U.S. Food and Drug Administration (FDA), as well as considerations in the EU and the UK. Understanding Potency Assays in CGT…

Inspection Readiness of CGT Manufacturing Sites for First BLA Submissions As cell and gene therapy (CGT) products evolve into mainstream medical offerings, ensuring compliance with regulatory expectations becomes paramount for manufacturers. For companies approaching their first Biologics License Application (BLA) submission, being inspection-ready is critical, particularly in regard to potency assays and release specifications. This article serves as a step-by-step regulatory tutorial for leaders in regulatory, CMC, clinical, and quality assurance (QA) roles, detailing the necessary frameworks under 21 CFR Parts 210 and 211 applicable to CGT manufacturing. Understanding CGT Manufacturing Regulations: An Overview The production of cell and gene…

Digital Tools and PAT Concepts Emerging in CGT Manufacturing Control The regulatory landscape surrounding cell and gene therapy (CGT) manufacturing is evolving swiftly, necessitating a clear understanding of the requirements outlined in 21 CFR Parts 210 and 211. This article offers a comprehensive step-by-step guide highlighting the integration of digital tools and Process Analytical Technology (PAT) concepts in CGT manufacturing control, focusing on potency assays and release specifications. Understanding CGT Manufacturing and Regulatory Framework Cell and gene therapies represent a novel approach to treating diseases at their genetic roots, often requiring specific manufacturing processes to ensure the quality and efficacy…

Global CMC Expectations for CGT under FDA, EMA, and MHRA In the burgeoning field of cell and gene therapy (CGT), the expectations for Chemistry, Manufacturing, and Controls (CMC) are crucial in ensuring that products are safe, effective, and manufactured consistently. Regulatory authorities such as the FDA, EMA, and MHRA have established frameworks that guide CGT manufacturers in developing their products. This article provides a comprehensive tutorial on the CMC expectations for CGT under the FDA (21 CFR Parts 210 and 211), while also drawing comparisons with EMA and MHRA guidelines where relevant. Understanding CGT Manufacturing Potency Assays CGT manufacturing involves…

Fundamentals of CGT Manufacturing: Potency Assays and Release Specifications Under 21 CFR Parts 210 and 211 The landscape of cell and gene therapy (CGT) manufacturing is characterized by intricate regulatory frameworks that ensure product safety, efficacy, and quality. Compliance with the U.S. Food and Drug Administration (FDA) regulations, particularly 21 CFR Parts 210 and 211, is essential for any organization involved in the manufacturing of CGT products. This guide provides a comprehensive step-by-step overview of the key elements pertaining to CGT manufacturing, focusing particularly on potency assays and release specifications. Understanding the Regulatory Framework of CGT Manufacturing The FDA’s regulation…